注射用帕瑞昔布钠的冻干工艺研究

目的：研究注射用帕瑞昔布钠最佳冻干制备工艺条件。方法通过部分因子分析实验,以水分、有关物质、含量等为指标优化冻干工艺,其中考察因素为冻干时间和干燥工艺,每个因素取3个水平。结果注射用帕瑞昔布钠的最佳冻干工艺条件为：真空度25 Pa,-40℃预冻4 h,0℃真空干燥15 h,35℃再干燥10 h即得。所制得注射用帕瑞昔布钠粉针剂经加速1、2、3月后性状、含量等指标无明显变化。结论选定的工艺可行,产品符合药典注射剂项下的各项要求。     

复方骨肽注射液联合玻璃酸钠治疗膝关节骨性关节炎的临床研究

目的 探讨复方骨肽注射液联合玻璃酸钠注射液治疗膝关节骨性关节炎的临床疗效。方法 选取2013年6月—2015年6月榆林市第一医院收治的膝关节骨性关节炎患者192例,随机分为玻璃酸钠组、骨肽组和联合组,每组各64例。玻璃酸钠组清除关节积液后关节腔内注射玻璃酸钠注射液,25 mg/次,1次/周,治疗5周;骨肽组静脉滴注复方骨肽注射液,4~10 m L加入生理盐水250 m L中,1次/d,治疗20 d。联合组采用玻璃酸钠注射液和复方骨肽注射液联合治疗,用法用量、疗程同玻璃酸钠组和骨肽组。观察3组的临床疗效,比较血清学指标和视觉模拟评分(VAS)情况。结果 治疗后,玻璃酸钠组、骨肽组和联合组总有效率分别为73.44%、75.00%、90.63%,联合组总有效率明显优于玻璃酸钠组和骨肽组,3组比较差异有统计学意义(P0.05)。治疗后,3组基质金属蛋白酶-3(MMP-3)、基质金属蛋白酶抑制剂-1(TIMP-1)和肿瘤坏死因子-α(TNF-α)水平均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且联合组这些指标下降程度明显优于玻璃酸钠组和骨肽组,3组比较差异具有统计学意义(P0.05)。治疗后,3组VAS评分均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且联合组VAS评分下降程度明显优于玻璃酸钠组和骨肽组,3组比较差异具有统计学意义(P0.05)。结论 静脉滴注复方骨肽注射液联合关节腔注射玻璃酸钠注射液治疗膝关节骨性关节炎具有较好的临床疗效,能改善临床症状,调节血清学指标,具有一定的临床推广应用价值。     

黏膜下注射不同剂量地塞米松改善下颌第三磨牙拔除术后症状的疗效观察

目的研究不同剂量地塞米松黏膜下注射对下颌第三磨牙拔除术后症状的临床疗效。方法选取2016年8月—2016年11月复旦大学附属中山医院和上海市静安区牙病防治所收治的拔除下颌第三磨牙患者156例,随机分为对照组(53例)、地塞米松4 mg组(51例)和地塞米松8 mg组(52例)。对照组术前于下颌第三磨牙黏膜周围1 cm范围内注射生理盐水。地塞米松4 mg组术前于下颌第三磨牙黏膜周围1 cm范围内注射地塞米松磷酸钠注射液4 mg。地塞米松8 mg组术前于下颌第三磨牙黏膜周围1 cm范围内注射地塞米松磷酸钠注射液8 mg。观察3组的第三磨牙拔除术后症状严重度(Po SSe)量表评分,比较3组的术后肿胀程度和最大张口程度。结果治疗后,地塞米松4 mg组和地塞米松8 mg组饮食、言语、肿胀、疼痛、日常生活评分和总评分明显低于对照组,3组比较差异有统计学意义(P0.05);且地塞米松8 mg组这些观察指标下降程度明显优于地塞米松4 mg组,两组比较差异具有统计学意义(P0.05)。治疗后,地塞米松8 mg组1级肿胀占比明显高于对照组和地塞米松4 mg组,而3、4级肿胀明显低于对照组和地塞米松4 mg组,3组比较差异具有统计学意义(P0.05)。术后1周,地塞米松4 mg组和地塞米松8 mg组最大张口程度明显大于对照组,3组比较差异具有统计学意义(P0.05)。结论黏膜下注射地塞米松可改善下颌第三磨牙拔除术后症状,可减少术后肿胀程度,增加术后1周最大张口程度,且地塞米松8 mg优于地塞米松4 mg,具有一定的临床推广应用价值。     

氟对大鼠免疫器官的影响及“抗氟灵”对氟拮抗作用的研究

本文研究了对大鼠免疫器官的影响及“抗氟灵”对氟的拮抗作用。２４只大鼠被随机分成３组,Ａ组为阴性对照组,Ｂ组对染氟组,Ｃ组为氟加“抗氟灵”组,观察与检测了所有动物的胸腺及脾脏的蛋白质含量,脏器重量,脏器系数及形态学变化。结果显示;Ｂ组动物胸腺与脾脏的蛋白含量,脏器重量,脏器系数均明显下降,胸腺皮质明显变薄,淋巴细胞稀疏;Ｃ组动物的这些指标变化不明显。     

Urothelial Damage and Tumor Initiation by Urinary Metabolites of Sodium o-Phenylphenate in the Urinary Bladder of Female Rats

Intravesical instillation of 2-phenyl-1,4-benzoquinone (PBQ), a metabolite of sodium o -phenylphenate (Na-OPP), at a concentration of 0.1% in saline caused acute epithelial injury, prolonged inflammation and epithelial hyperplasia in female F344 rats. Ten such instillations of PBQ within 5 weeks resulted in the development of preneoplastic lesions of the urinary bladder epithelium when followed by 5% sodium saccharin feeding for 31 weeks. Since neither urothelial damage nor tumor-initiating activity was observed with either Na-OPP itself or another metabolite, phenylhydroquinone, PBQ may play an essential role in Na-OPP urinary bladder carcinogenesis.     

HPLC双波长法测定丸剂1号中芦丁、阿魏酸钠的含量

目的：研究高效液相色谱法同时测定丸剂1号中芦丁及阿魏酸钠的含量方法。方法：采用YMC-ODS-A（4．6mm×250mm,5μm）色谱柱,柱温25℃,流动相为甲醇-水-36％醋酸（40：60：1．5）,流速为1．0mL·min^-1,检测波长为λ1=257nm（芦丁）,λ2=322nm（阿魏酸钠）。结果：芦丁、阿魏酸钠进样量分别在0．02—0．26μg（r=0．9998）、0．01～0．27μg（r=0．9998）与各自峰面积呈良好线性关系。二者的平均回收率分别为99．63％（RSD=0．59％）,99．77％（RSD=0．98％）。结论：本方法简便、准确、重复性好,可作为丸剂1号的质量控制方法。     

芒硝外用抗炎作用研究

目的:观察芒硝外用对小鼠皮肤毛细血管通透性及家兔耳静脉炎的影响。方法:采用二甲苯致炎,小鼠静脉注射伊文思蓝,紫外测定皮肤中伊文思蓝的含量,间接反应皮肤毛细血管通透性;兔耳静脉输注甘露醇溶液造兔耳静脉炎模型,观察芒硝溶液外用对炎症的影响。结果:大、中、小剂量芒硝溶液均能显著性降低小鼠皮肤内伊文思蓝含量(P0.01);静脉输注甘露醇造模48h后,小剂量芒硝溶液组能显著改善静脉炎病理变化,大、中剂量芒硝溶液组能明显改善静脉炎病理变化;造模96h后,大、中、小剂量芒硝溶液组均能显著改善静脉炎病理变化。结论:芒硝溶液外用对急性炎症有好的抑制作用,对兔耳静脉炎有好的治疗作用。     

头孢哌酮/他唑巴坦钠在含果糖氯化钠注射液和转化糖注射液中的稳定性考察

目的:考察头孢哌酮/他唑巴坦钠在含果糖氯化钠注射液和转化糖注射液中的稳定性。方法:采用高效液相色谱(HPLC)法测定头孢哌酮/他唑巴坦钠与含果糖氯化钠注射液和转化糖注射液配伍6h内的含量,并考察其外观、pH值变化。结果:头孢哌酮/他唑巴坦钠与2种注射液配伍后,6h内其含量变化不大,溶液澄清,pH值基本稳定。结论:头孢哌酮/他唑巴坦钠可与含果糖氯化钠注射液和转化糖注射液配伍使用。     

HPLC法测定萘普生钠片的含量

目的：采用高效液相色谱法测定萘普生钠的含量。方法：色谱柱为DiamonsilC18（5μm,200mm×4.6mm）,流动相为甲醇-水（75∶25）;流速1.0ml/min;检测波长为332nm。结果：萘普生钠在45.02～162.07μg的范围内线性关系良好,r=0.9998（n=7）,平均回收率为98.9%（RSD为0.82%,n=6）。结论：本方法操作简便、精密度好、结果准确,无其他成分的干扰,可用于测定萘普生钠片的含量。     

Primary sequence and functional expression of a novel β subunit of the P-ATPase gene family

The cortical collecting tubule (CCT) of the mammalian kidney reabsorbs sodium and potassium, processes that are mediated by Na/K-ATPase and H/K-ATPase. CCT is also an important site for proton secretion, which is driven, in part, by H/K-ATPase. Na/K-ATPase and H/K-ATPase are members of the ion-motive P-ATPase gene family. They are closely related plasma membrane proteins which consist of heterodimers. The urinary bladder of the toad Bufo marinus is the amphibian counterpart of mammalian CCT. We have previously characterized a ouabain-resistant Na/K-ATPase [see ref. 17], from TBM cells, a clonal cell line derived from the toad bladder, which expresses transepithelial sodium transport. In the present study, we report the primary sequence and functional expression of a novel subunit ( _bladder= _bl) isolated from a toad bladder epithelial cell cDNA library. The deduced polypeptide is 299 amino acids in length and has a predicted molecular mass of 33 kDa. The _bl protein exhibits 35% amino acid identity to the previously characterized ₁ of B. marinus Na/K-ATPase and 39% identity with ₃ of B. marinus Na/K-ATPase. It shares 38% identity with the mammalian gastric H/K-ATPase and 52% with the mammalian ₂ Na/K-ATPase. Northern blot analysis shows that a 1.4×10³-base mRNA is expressed at a high level in bladder epithelial cells and eye and at a trace level in kidney; it is not detectable in significant amounts in the stomach, colon and small intestine. The _bl subunit can associate with the ₁ subunit of B. marinus Na/K-ATPase to form a functional sodium pump in the Xenopus laevis oocyte. Our data indicate that, in addition to the known ₁ and ₃ isoforms, a third distinct isoform of the subunit is present in the bladder epithelium. This new isoform could be functionally associated with subunits of either Na/K- or H/K-ATPase.